Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 239Sarcoma 28Gastrointestinal 13Thoracic 11Lymphoid 9Gynecologic 9Genitourinary 9Breast 8Dermatologic 7Myeloid 4Head & Neck 3Other hematologic neoplasm 2Endocrine 2Plasma cell 1Other solid neoplasm 1NET 1Classical hematology 1

Conditions

Advanced Solid Tumors 64Advanced Solid Tumor 54Solid Tumor 50Solid Tumors 40Mesothelioma 40Mesothelioma, Malignant 37Hematopoietic and Lymphatic System Neoplasm 21Solid Tumor, Adult 16Carcinoma, Non-Small-Cell Lung 15Melanoma 13Malignant Solid Neoplasm 13Ovarian Neoplasms 12Sarcoma 10Retinoblastoma 9Pancreatic Neoplasms 9Lung Neoplasms 8Advanced Malignant Solid Neoplasm 8Small Cell Lung Carcinoma 7Kidney Neoplasms 7Colorectal Neoplasms 7Cholangiocarcinoma 7Carcinoma, Renal Cell 7Advanced or Metastatic Solid Tumors 7Stomach Neoplasms 6Solid Tumours 6Carcinoma, Hepatocellular 6Advanced/Metastatic Solid Tumors 6Advanced Malignant Solid Tumor 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × Other solid neoplasm × 90 days × Clear all
NCT05275478 2026-04-15

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Tango Therapeutics, Inc.

Phase 1/2 Terminated
110 enrolled
CNSGastrointestinalOther solid neoplasmSarcomaThoracic

Glioblastoma, Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡